EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Differentiating Upper Tract Urothelial Carcinoma with Synchronous or Metachronous Bladder Cancer

Sara Meireles iD, Carolina Dias iD, Ana Marques, João Silva, Luís Costa iD, José Manuel Lopes iD, Paula Soares iD

Current Issues in Molecular Biology · 26.03.2026 · 48 (4) · 345

DOI: 10.3390/cimb48040345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 26.03.2026. Verfasst von Sara Meireles und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research and Innovation in Health (i3S), University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PRR-Plano de 249 Recuperação e Resiliência e pelos Fundos Europeus NextGenerationEU;Institute for Research and Innovation in Health Sciences;The Porto Comprehe…, PRR—Plano de Recuperação e Resiliência e pelos Fundos Europeus NextGenerationEU, Institute for Research and Innovation in Health Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The features of patients with multiple urothelial tumors remain to be elucidated. We intend to differentiate primary upper tract urothelial carcinoma with synchronous urothelial bladder cancer (UTUC + sUBC) and UTUC with metachronous UBC (UTUC + mUBC) cases to determine whether these temporal patterns reflect biologically distinct processes. A subgroup analysis of a retrospective cohort of UTUC (n = 114) was performed comparing UTUC + sUBC (n = 14) with UTUC + mUBC (n = 29). IHC expression of cytokeratin 5/6 (CK5/6), CK20, GATA3, and p53 was evaluated to assess relevant subtypes. Genetic characterization comprised TERTp, FGFR3, RAS, and TP53 status. Kaplan–Meier analyses estimated the progression-free survival (PFS) and overall survival (OS) of both UTUC subgroups, and the log-rank test was used to assess differences between subgroups. Our study reveals no significant differences in phenotype or genomic profile between synchronous and metachronous UTUC-UBC cases (p > 0.05). Nevertheless, patients with synchronous UBC revealed significantly worse outcomes in PFS (2y-PFS 23.1% vs. 52.1%, p = 0.029) and OS (2y-OS 40.4% vs. 84.4%, p = 0.016) than those with metachronous disease. These discrepancies could arise from as yet-uncharacterized molecular features or microenvironmental influences.

Schlagwörter

Stichwörter der Autor:innen

bladder cancermetachronousprognosissynchronousupper tract urothelial carcinoma

Autor:innen und Institutionen

  • Institute for Research and Innovation in Health (i3S), University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
  • Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Rua Júlio Amaral de Carvalho 45, 4200-135 Porto, Portugal.
  • Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
  • Medical Oncology Department, Centro Hospitalar Universitário de São João (CHUSJ), Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
  • Pathology Department, Centro Hospitalar Universitário de São João (CHUSJ), Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
  • Urology Department, Centro Hospitalar Universitário de São João (CHUSJ), Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.

ORCID-Profile: Sara Meireles, Carolina Dias, Luís Costa, José Manuel Lopes, Paula Soares

Förderung

  • PRR-Plano de 249 Recuperação e Resiliência e pelos Fundos Europeus NextGenerationEU;Institute for Research and Innovation in Health Sciences;The Porto Comprehe…
  • PRR—Plano de Recuperação e Resiliência e pelos Fundos Europeus NextGenerationEU
  • Institute for Research and Innovation in Health Sciences
  • The Porto Comprehensive Cancer Center”—Consórcio PORTO.CCC—Porto. Comprehensive Cancer Center Raquel Seruca https://ror.org/02kcc1z29

Zitieren

APA

Meireles, S., Dias, C., Marques, A., Silva, J., Costa, L., Lopes, J. M., & Soares, P. (2026). Differentiating Upper Tract Urothelial Carcinoma with Synchronous or Metachronous Bladder Cancer. Current Issues in Molecular Biology, 48(4), 345. https://doi.org/10.3390/cimb48040345

Vancouver

Meireles S, Dias C, Marques A, Silva J, Costa L, Lopes JM, et al. Differentiating Upper Tract Urothelial Carcinoma with Synchronous or Metachronous Bladder Cancer. Current Issues in Molecular Biology. 2026;48(4):345. doi:10.3390/cimb48040345

BibTeX
@article{Meireles2026,
  author = {Meireles, Sara and Dias, Carolina and Marques, Ana and Silva, João and Costa, Luís and Lopes, José Manuel and Soares, Paula},
  title = {Differentiating Upper Tract Urothelial Carcinoma with Synchronous or Metachronous Bladder Cancer},
  journal = {Current Issues in Molecular Biology},
  year = {2026},
  volume = {48},
  number = {4},
  pages = {345},
  doi = {10.3390/cimb48040345}
}
Kostenlos starten →